The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Strizhakov L.A.

Klinika nefrologii, vnutrennikh i professional'nykh zabolevaniĭ, Universitetskaia klinicheskaia bol'nitsa #3 Pervogo MGMU im. I.M. Sechenova, Moskva

Karpov S.Yu.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Lopatkina T.N.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Tanashchuk E.L.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Taranova M.V.

Klinika nefrologii, vnutrennikh i professional'nykh zabolevaniĭ, Universitetskaia klinicheskaia bol'nitsa #3 Pervogo MGMU im. I.M. Sechenova, Moskva

Myocardial injury associated with chronic hepatitis C: Clinical types and pathogenetic components

Authors:

Strizhakov L.A., Karpov S.Yu., Fomin V.V., Lopatkina T.N., Tanashchuk E.L., Taranova M.V.

More about the authors

Journal: Therapeutic Archive. 2016;88(4): 105‑111

DOI: 10.17116/terarkh2016884105-111

Read: 7324 times

Download PDF (RU)
Contact the author
Table of contents

MYOCARDIAL INJURY ASSOCIATED WITH CHRONIC HEPATITIS C: CLINICAL TYPES AND PATHOGENETIC COMPONENTS
MYOCARDIAL INJURY ASSOCIATED WITH CHRONIC HEPATITIS C: CLINICAL TYPES AND PATHOGENETIC COMPONENTS

To cite this article:

Strizhakov LA, Karpov SYu, Fomin VV, Lopatkina TN, Tanashchuk EL, Taranova MV. Myocardial injury associated with chronic hepatitis C: Clinical types and pathogenetic components. Therapeutic Archive. 2016;88(4):105‑111. (In Russ.)
https://doi.org/10.17116/terarkh2016884105-111

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Analysis of differential gene expression in myocardial tissue from patients with hype­rtrophic cardiomyopathy. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):17-23
Atrial fibrillation and left ventricular dysfunction: cause or consequence (analysis of the dila­ted cardiomyopathy regi­stry). Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(6):619-627
Abstract:

Heart injury is one of the extrahepatic manifestations of chronic hepatitis C (CHC). The paper gives Russian and foreign authors’ data on a relationship between CHC and myocardial injury. It discusses different pathogenetic components (the direct effect of the virus, immunological components), through which hepatitis C virus can induce myocarditis and cardiomyopathies in patients with CHC.

Keywords:

chronic hepatitis C
myocarditis
cardiomyopathy

Authors:

Strizhakov L.A.

Klinika nefrologii, vnutrennikh i professional'nykh zabolevaniĭ, Universitetskaia klinicheskaia bol'nitsa #3 Pervogo MGMU im. I.M. Sechenova, Moskva

Karpov S.Yu.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Lopatkina T.N.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Tanashchuk E.L.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Taranova M.V.

Klinika nefrologii, vnutrennikh i professional'nykh zabolevaniĭ, Universitetskaia klinicheskaia bol'nitsa #3 Pervogo MGMU im. I.M. Sechenova, Moskva

Close metadata

References:

  1. Matsumori A. Hepatitis C Virus Infection and Cardiomyopathies. Circ Rec. 2005;96:144-147.  doi:10.1161/01.res.0000156077.54903.67.
  2. Ignatova T, Aprosina Z, Serov V et al. Extrahepatic manifestations of hepatitis C. Terapevticheskii arkhive. 1998;11:9-16. (In Russ.)
  3. Ignatova T, Aprosina Z, Belokrinitckaya O et al Myocarditis, polymyositis, and Raynaud's syndrome in patients with chronic hepatitis C. Terapevticheskii arkhive. 1999;12:56-58. (In Russ.)
  4. Krel P, Aprosina Z, Belokrinickaya O et al. Myocarditis in chronic active hepatitis. Klinicheskaya meditsina. 1989;2:8-83. (In Russ.)
  5. Nikitin I, Storozhakov G. Chronic HBV, HCV, HDV-hepatitis — systemic infection. Terapevticheskii arkhive. 1998;2:80-82. (In Russ.)
  6. Fomin V, Nikulkina E, Sedov V, Girina S, Doletckii A, Moiseev S. Apical hypertrophic cardiomyopathy associated with HCV-infection. Terapevticheskii arkhive. 2011;1:24-29. (In Russ.)
  7. Kelbaek H, Eriksen J, Brynjolf I et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol. 1984;54(7):852-855.  doi:10.1016/s0002-9149(84)80220-9.
  8. Wong F, Liu P, Lilly L et al. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond). 1999;97(3):259-267.  doi:10.1042/cs0970259.
  9. Pozzi M, Carugo S, Boari G et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology. 1997;26(5):1131-1137. doi:10.1002/hep.510260507.
  10. Konysheva A, Saginova E, Moiseev S, Krasnova T, Abdurachmanov D. Diastolic dysfunction and changes in the QT interval in chronic hepatitis C virus. Rossiiskii zhurnal Gastroenterologii Hepatologii i Coloproctologii. 2012;22(6):38-43. (In Russ.)
  11. Lopatkina T, Strizhakov L, Konysheva A, Tanaschuk E, Taranova M, Moiseev S. Options for heart disease in chronic hepatitis C. Klinicheskaya farmakologiya i terapiya. 2014;4:90-93. (In Russ.)
  12. Richardson P, McKenna W, Bristow M et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task forse on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-842.  doi:10.1161/01.cir.93.5.841. 
  13. Matsumori A. Animal model: pathological findings and therapeutic consideration. In Banatvala JE. ed. Viral Infection of the Heart. London, UK: E. Arnold; 1993:351-362.  doi:10.1007/978-3-642-77891-9_31.
  14. Derugin M, Boitcov S. Chronic myocarditis. Elbi-S.Pb; 2005. (In Russ.)
  15. Blagova O, Nedostup A, Kogan E, Sulimov V. From the «idiopathic» atrial fibrillation to the formulation of nosological diagnosis. Clinical analysis of the therapeutic clinic in the faculty them. VN Vinogradov. Rare and diagnostically challenging disease in internal medicine. Moscow: GEOTAR Media; 2012. (In Russ.)
  16. Nedostup A, Blagova O, Kogan E, Sulimov V. Myocardial vasculitis: the path to diagnosis, clinical variants, attempts of pathogenetic therapy. Clinical analysis of the therapeutic clinic in the faculty them. VN Vinogradov. Rare and diagnostically challenging disease in internal medicine. Moscow: GEOTAR Media; 2012. (In Russ.)
  17. Kawano H, Kawai S, Nashijo T et al. An autopsy case of hypertrophic cardiomyopathy with pathological findings suggesting chronic myocarditis. Jpn Heart J. 1994;35:95-105.  doi:10.1536/ihj.35.95.
  18. Matsumori A, Matoba Y, Sasyama S. Dilated cardiomyopathy associated with hepatitis virus infection. Circulation. 1995;92:2519-2525. doi:10.1161/01.cir.92.9.2519.
  19. Matsumori A, Matoba Y, Nishino R et al. Detection of hepatitis C virus RNA from the heart of patient with hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 1996;222:678-682.  doi:10.1006/bbrc.1996.0803.
  20. Okabe M, Fukuda K, Arakava K, Kikuchi M. Chronic variant of myocarditis associated with HCV — РНК. Circulation. 1997;96:22-24.  doi:10.1161/01.cir.96.1.22.
  21. Teragaki M, Nishiguchi S, Takeuchi K et al. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels. 2003;18:167-170.  doi:10.1007/s00380-003-0705-0.
  22. Matsumori A. Role of hepatitis C virus in myocarditis and cardiomyopathies. Geriatr Cardiol. 2004;1:99-120.  doi:10.1007/3-540-30822-9_7.
  23. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.  doi:10.1016/s0140-6736(97)03079-1.
  24. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. J Card Fail. 2006;12(4):293-298.  doi:10.1016/j.cardfail.2005.11.004.
  25. Аntonelli A, Ferri C, Ferrari S. High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. J Viral Hepat. 2010;12:851-853.  doi:10.1111/j.1365-2893.2009.01237.x.
  26. Bristow MR. Tumor Necrosis Factor-α and Cardiomyopathy. Circulation. 1998;97:1340-1341. doi:10.1161/01.cir.97.14.1340. 
  27. Billingham ME, Tazelaar HD. The morphological progression of viral myocarditis. Postgrad Med J. 1986;62:581-584.  doi:10.1136/pgmj.62.728.581. 
  28. O’Connell JB. The role of myocarditis in end-stage dilated cardiomyopathy. Texas Heart Inst J. 1987;14:268-275.
  29. Kawai C. From myocarditis to cardiomyopathy: mechanism of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091-1100. doi:10.1161/01.cir.99.8.1091. 
  30. Neumann DA, Lane JR, Alen GS et al. Viral myocarditis leading to cardiomyopathy: do cytokines contribuye to pathogenesis? Clin Immunol Immunopathol. 1993;68:181-190.  doi:10.1006/clin.1993.1116. 
  31. Gluck B, Schmidtke M, Merkle I et al: Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol. 2001;33:1615-1626. doi:10.1006/jmcc.2001.1416. 
  32. Matsumori A, Yamada T, Suzuki H et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.  doi:10.1136/hrt.72.6.561. 
  33. Satoh M, Tamura G, Segawa I et al: Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch. 1996;427:503-509.  doi:10.1007/bf00199511. 
  34. Kelleher DM, Telfor SR, Criscione L et al. Cytokines in murine lyme carditis: Th1 cytokine expression follows expression of proinflammatory cytokines in a susceptible mouse strain. J Infect Dis. 1998;177:242-246.  doi:10.1086/517364. 
  35. Calabrese F, Carturan E, Chimenti C et al. Overexpression of tumor necrosis factor (TNF) alpha and TNF-alpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol. 2004;17:1108-1118. doi:10.1038/modpathol.3800158. 
  36. Torre-Aminone G, Kapadia S, Lee J et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.  doi:10.1161/01.cir.93.4.704. 
  37. Bryant D, Becker L, Richardson J et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375-1381. doi:10.1161/01.cir.97.14.1375. 
  38. Torre-Aminone, G, Kapadia S, Lee J et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493. doi:10.1161/01.cir.92.6.1487. 
  39. Krown KA, Yasui K, Brooker MJ et al. TNF alpha receptor expression in rat cardiac myocytes: TNF alpha inhibition of L-type Ca2+ current and Ca2+ transients. FEBS Lett. 1995;376:24-30.
  40. Hare JM, Keaney JF Jr, Balligand JL et al. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest. 1995;95:360-366.  doi:10.1172/jci117664. 
  41. Hong X, Yu RB, Sun NX et al. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2005;11:7302-7307. doi:10.3748/wjg.v11.i46.7302. 
  42. Naruse TK, Inoko H. HLA and hepatitis C virus positive cardiomyopathy. Nippon Rinsho. 2000;58:212-217.
  43. Shichi D, Kikkawa EF, Ota M et al. The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens. 2005;66:200-208.  doi:10.1111/j.1399-0039.2005.00457.x. 
  44. O’Garra N, Robinson D. Development and function of T helper 1 cells. Adv Immunol. 2004;83:133-162.  doi:10.1016/s0065-2776(04)83004-9. 
  45. Izumi T, Takehana H, Matsuda S et al. Experimental autoimmune myocarditis and its pathomechanism. Herz. 2000;25(3):274-278.  doi:10.1007/s000590050020. 
  46. Mourad W, Al-Daccak R, Chatila T, Geha RS: Staphylococcal superantigens as inducers of signal transduction in MHC class II-positive cells. Semin Immunol. 1993;5:47-55.  doi:10.1006/smim.1993.1007.
  47. Mourad W, Mehindate K, Schall TJ, McColl SR. Engagement of major histocompatibility complex class II molecules by superantigenes induces inflammatory cytokines gene expression in human rheumatoid fi-broblast-like synoviocytes. J Exp Med. 1992;175:613-616.  doi:10.1084/jem.175.2.613. 
  48. Li H, Lera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. Annu Rev Immunol. 1999;17:435-466.  doi:10.1146/annurev.immunol.17.1.435. 
  49. Al-Daccak R, Mehindate K, Hebert J et al. Mycoplasma arthritidis-derived superantigen induces proinflammatory monokine gene expression in the THP-1 human monocytic cell line. Infect Immun. 1994;62:2409-2416.
  50. Mehindate K, Al-Daccak R, Schall TJ, Mourad W. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fi broblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone. J Biol Chem. 1994;269:32063-32069.
  51. Alvarez-Ossorio L, Johannsen M, Alvarez-Ossorio R et al. Cytokine induction by Micoplasma arthritidis-derived superantigen (MAS), but not TSST-1 or SEC-3, is correlated to certain HLA-DR types. Scand J Immunol. 1998;47:43-47.  doi:10.1046/j.1365-3083.1998.00252.x. 
  52. Rink L, Nicklas W, Luhm J et al. Induction of proinflammatory cytokine network by Mycoplasma arthritidis-derived superantigen (MAS). J Interferon Cytokine Res. 1996;16:861-868.  doi:10.1089/jir.1996.16.861. 
  53. Matsumori A, Sasayama S. Never Aspects of Pathogenesis of Heart Failure: Hepatitis C virus infection in myocarditis and cardiomyopathy. J Card Fail. 1996;2(4 Suppl.):187-194.  doi:10.1016/s1071-9164(96)80076-5.
  54. Frustaci A, Calabrese F, Chimenti C et al. Lone Hepatitis C virus Myocarditis responsive to immunosuppressive therapy. Chest. 2002;122:1348-1356. doi:10.1378/chest.122.4.1348.
  55. Omura T, Yoshiyama M, Hayashi T et al. Core protein of hepatitis c virus induced cardiomyopathy. Circ Res. 2005;96(2):148-150.  doi:10.1161/01.res.0000154263.70223.13. 
  56. Meldrum DR, Dinarello CA, Cleveland JC Jr et al. Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery. 1998;124(2):291-296.  doi:10.1016/s0039-6060(98)70133-3. 
  57. Korenaga M, Okuda M, Otani K et al. Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol. 2005;39(4 Suppl.2):162-166.  doi:10.1097/01.mcg.0000155517.02468.46. 
  58. Okuda M, Li K, Beard MR, Showalter LA et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122(2):366-375.  doi:10.1053/gast.2002.30983.
  59. Korenaga M, Wang T, Li Y et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem. 2005;280(45):37 481-37 488.  doi:10.1074/jbc.m506412200.
  60. Taylor ER, Hurrell F, Shannon RJ et al. Reversible Glutathionylation of Complex I Increases Mitochondrial Superoxide Formation. J Biol Chem. 2003;278(22):19603-19610. doi:10.1074/jbc.m209359200.
  61. Meldrum DR, Dinarello CA, Cleveland JC Jr et al. Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery. 1998;124(2):291-296.  doi:10.1016/s0039-6060(98)70133-3. 
  62. Ungvari Z, Gupte SA, Recchia FA et al. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3(3):221-229.  doi:10.2174/1570161054368607.
  63. Sam F, Kerstetter DL, Pimental DR et al. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail. 2005;11(6):473-480.  doi:10.1016/j.cardfail.2005.01.007.
  64. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15(22):2922-2933.
  65. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene. 1999;17:3261-3270. doi:10.1038/sj.onc.1202568.
  66. Adhihetty PJ, Hood DA: Mechanisms of Apoptosis in Skeletal Muscles. Basic Appl Myol. 2003;13(4):171-179.
  67. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 2015;49(5):566-581.  doi:10.1177/1060028015570729.
  68. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med. 2014;370(3):211-221.  doi:10.1056/nejmx140011.
  69. Buti M, Llaneras J, Riveiro-Barciela M, Esteban R. Therapy for hepatitis C genotype 3: moving forward. J Viral Hepat. 2015;22(9):683-690.  doi:10.1111/jvh.12419.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.